pre-IPO PHARMA

COMPANY OVERVIEW

Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based London,


LOCATION

  • London, , UK

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.prokarium.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    flerie-invest future-fund korea-investment-partners riyadh-valley-company


    PRESS RELEASES


    Feb 9, 2023

    Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform


    Oct 5, 2022

    Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies


    Mar 2, 2022

    Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the Treatment of Bladder Cancer


    Jan 26, 2022

    Prokarium Expands RandD Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline


    Nov 11, 2021

    Prokarium Shares Preclinical Proof-of-Concept Data on Its Microbial Immunotherapy Bladder Cancer Program at SITC 2021


    For More Press Releases


    Google Analytics Alternative